HomeCompareCITE vs ABBV

CITE vs ABBV: Dividend Comparison 2026

CITE yields 16.88% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $44.5K in total portfolio value· pulled ahead in Year 7
10 years
CITE
CITE
● Live price
16.88%
Share price
$11.85
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$60.2K
Annual income
$4,755.24
Full CITE calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — CITE vs ABBV

📍 ABBV pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCITEABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CITE + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CITE pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CITE
Annual income on $10K today (after 15% tax)
$1,434.60/yr
After 10yr DRIP, annual income (after tax)
$4,041.95/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, ABBV beats the other by $17,824.92/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CITE + ABBV for your $10,000?

CITE: 50%ABBV: 50%
100% ABBV50/50100% CITE
Portfolio after 10yr
$82.4K
Annual income
$15,240.48/yr
Blended yield
18.48%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CITE
No analyst data
Altman Z
2.5
Piotroski
2/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CITE buys
0
ABBV buys
0
No recent congressional trades found for CITE or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCITEABBV
Forward yield16.88%3.12%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$60.2K$104.7K
Annual income after 10y$4,755.24$25,725.73
Total dividends collected$31.2K$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CITE vs ABBV ($10,000, DRIP)

YearCITE PortfolioCITE Income/yrABBV PortfolioABBV Income/yrGap
1$12,388$1,687.76$11,559$438.51+$829.00CITE
2$15,209$1,953.98$13,494$640.86+$1.7KCITE
3$18,516$2,242.03$15,951$945.97+$2.6KCITE
4$22,363$2,550.92$19,152$1,413.89+$3.2KCITE
5$26,807$2,879.37$23,443$2,146.38+$3.4KCITE
6$31,910$3,225.86$29,391$3,321.96+$2.5KCITE
7← crossover$37,732$3,588.65$37,948$5,265.87$216.00ABBV
8$44,339$3,965.84$50,795$8,596.74$6.5KABBV
9$51,798$4,355.40$71,034$14,549.41$19.2KABBV
10$60,179$4,755.24$104,715$25,725.73$44.5KABBV

CITE vs ABBV: Complete Analysis 2026

CITEStock

Cartica Acquisition Corp does not have any significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to identify and complete a business combination in the technology sector in India. Cartica Acquisition Corp was incorporated in 2021 and is based in Washington, the District of Columbia.

Full CITE Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CITE vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CITE vs SCHDCITE vs JEPICITE vs OCITE vs KOCITE vs MAINCITE vs JNJCITE vs MRKCITE vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.